Roche Divarasib Phase 3 Trial: What It Means for Lumakras and Krazati
The Roche divarasib Phase 3 trial beat sotorasib and adagrasib on survival. What it means for competitors, analysts and the untreated-patient market.
Tag: KRAS G12C lung cancer
Read More